 Connection
Jonathan Gutman to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Jonathan Gutman has written about Leukemia, Myeloid, Acute.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
5.154 |
|
|
|
-
Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 10 01; 108(10):2616-2625.
Score: 0.563
-
Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023 08; 58(8):849-854.
Score: 0.547
-
Gutman JA. How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML. Best Pract Res Clin Haematol. 2022 12; 35(4):101411.
Score: 0.529
-
Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax?+?Azacitidine Versus Intensive Chemotherapy. Transplant Cell Ther. 2022 10; 28(10):694.e1-694.e9.
Score: 0.519
-
Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, Abbott D, Smith CA, Gutman JA. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022 02; 57(2):160-166.
Score: 0.492
-
Gutman JA, Pollyea DA. Hypomethylating agents with venetoclax: have we discovered the holy grail? Curr Opin Hematol. 2020 Mar; 27(2):76-80.
Score: 0.440
-
Gutman JA, Hoffner B. A novel CCAAT/enhancer binding protein a germline variant in a case of acute myeloid leukemia. Leuk Lymphoma. 2012 May; 53(5):1006-7.
Score: 0.250
-
Gutman JA, Allen CT, Madtes DK, Schramm J, Delaney C. Pulmonary veno-occlusive disease following reduced-intensity cord blood transplantation. Bone Marrow Transplant. 2008 Oct; 42(8):559-61.
Score: 0.197
-
Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, Pollyea DA. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. 2024 06 01; 109(6):1766-1778.
Score: 0.148
-
Islam N, Reuben JS, Dale J, Gutman J, McMahon CM, Amaya M, Goodman B, Toninato J, Gasparetto M, Stevens B, Pei S, Gillen A, Staggs S, Engel K, Davis S, Hull M, Burke E, Larchick L, Zane R, Weller G, Jordan C, Smith C. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine. JCO Clin Cancer Inform. 2022 09; 6:e2200030.
Score: 0.131
-
Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021 12 28; 5(24):5565-5573.
Score: 0.125
-
Ho AP, Ho BE, Berg MP, Gutman JA, Draper NL. Blood type change identifies late dominance reversal of chimerism after double umbilical cord blood transplantation with review of the literature. Transfusion. 2021 03; 61(3):960-967.
Score: 0.118
-
Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax?+?azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2021 06; 62(6):1466-1473.
Score: 0.116
-
Kent A, Vasu S, Schatz D, Monson N, Devine S, Smith C, Gutman JA, Pollyea DA. Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse. Blood Adv. 2020 07 14; 4(13):3102-3108.
Score: 0.113
-
Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020 04; 10(4):536-551.
Score: 0.109
-
Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DA. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019 10 22; 3(20):2911-2919.
Score: 0.107
-
Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, Jordan CT, Smith C, Pollyea DA. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Leuk Res. 2019 06; 81:43-49.
Score: 0.103
-
Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, Jordan CT. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018 12; 24(12):1859-1866.
Score: 0.100
-
Sharma P, Pollyea DA, Smith CA, Purev E, Kamdar M, Haverkos B, Sherbenou D, Rabinovitch R, Hammes A, Gutman JA. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. Biol Blood Marrow Transplant. 2018 08; 24(8):1671-1677.
Score: 0.097
-
Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. J Biol Chem. 2016 Oct 14; 291(42):21984-22000.
Score: 0.086
-
Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014 Aug; 99(8):1277-84.
Score: 0.075
-
Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Apr; 20(4):549-55.
Score: 0.072
-
Petz LD, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, Gutman J, Querol S, Clark P, Tonai R, Santos S, Bravo A, Spellman S, Gragert L, Rossi J, Li S, Li H, Senitzer D, Zaia J, Rosenthal J, Forman S, Chow R. Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biol Blood Marrow Transplant. 2013 Mar; 19(3):393-7.
Score: 0.066
-
Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein ID, Riddell SR, Delaney C. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood. 2010 Jan 28; 115(4):757-65.
Score: 0.053
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|